Clinical Trials

50 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT07235293 2026-04-09

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

90 enrolled

Colorectal Neoplasms

NCT07136077 2026-04-06

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

20 enrolled

Colorectal Neoplasms, Neoplasm, Residual

NCT06497985 2026-03-19

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Phase 3 Recruiting

430 enrolled

Colorectal Neoplasms

NCT07011576 2026-03-18

FRUITFUL

60 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06992258 2026-03-17

FRUITION

120 enrolled

Colorectal Neoplasms

NCT06562543 2026-02-27

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Phase 4 Recruiting

78 enrolled

Colorectal Neoplasms

NCT07392346 2026-02-11

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

68 enrolled

Gastric Cancer Adenocarcinoma Metastatic

NCT07270991 2026-02-05

FRUQUITAS

Phase 3 Recruiting

324 enrolled

Tumor-Agnostic

Neoplasms

NCT05867420 2026-01-27

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

594 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT05954429 2026-01-22

A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study

50 enrolled

Colorectal Neoplasms

NCT05405595 2026-01-07

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

186 enrolled

Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT06856837 2025-12-12

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

140 enrolled

Colorectal Neoplasms

NCT07130903 2025-11-10

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

102 enrolled

Metastatic Colorectal Adenocarcinoma

NCT06441565 2025-07-30

Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer

Phase 2/3 Recruiting

84 enrolled

Colorectal Neoplasms

NCT06329973 2025-07-17

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

70 enrolled

Metastatic Gastroesophageal Junction Adenocarcinoma

NCT06356584 2025-06-26

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

62 enrolled

Colorectal Neoplasms

NCT05771181 2025-06-12

Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients

25 enrolled

Colorectal Neoplasms

NCT07003022 2025-06-04

Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

40 enrolled

Colonic Neoplasms

NCT06980532 2025-05-20

Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer

42 enrolled

Colorectal Neoplasms

NCT05941325 2025-05-18

A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

20 enrolled

Sarcoma

NCT05848739 2025-05-11

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Phase 1 Recruiting

130 enrolled